Omnihealth Practice

ONCOLOGY

CAPItello-281: FDA approves capivasertib + abiraterone for PTEN-deficient advanced prostate cancer

28 Aug 2026

Optimizing diagnosis and surveillance of von Hippel-Lindau disease: HKSUO-HKNOS joint expert consensus

27 Jul 2026

Optimizing management of locally advanced and mRCC: HKUA-HKSUO joint expert consensus

24 Jun 2026

Cabozantinib combinations leading the way in RCC: Transformative therapies backed by real-world success

20 May 2026

First glimpse of zolbetuximab-based chemo-immunotherapy shows promise in CLDN18.2- and PD-L1-positive advanced G/GEJ cancer: ILUSTRO phase 2 data from ASCO GI 2026

22 Feb 2026

Dual immunotherapy combination in pre-treated HCC: A case study in achieving 10-year remission

26 Jan 2026

Lenvatinib + pembrolizumab delivers sustained efficacy in aRCC regardless of baseline bone metastases: Final analysis from CLEAR

22 Dec 2025

Parity and breastfeeding establish durable CD8⁺ T cell-mediated protection in TNBC

16 Dec 2025

Lighting the path: How sentinel nodes guide EC care

26 Nov 2025

Osimertinib + plat-pem shows consistent OS benefits in EGFRm advanced NSCLC irrespective of poor baseline prognostic factors: Exploratory OS analyses from FLAURA2

20 Nov 2025

Lighting the path: How sentinel nodes guide EC care

In a recent expert discussion with Professor Nirmala Kampan, she shared her perspectives on the evolving role of this technique, from evidence-based outcomes to future innovation and directions in patient-centered care in EC.

26 Nov 2025

Professor Dr. Nirmala Kampan

Consultant Obstetrician & Gynecologist,
Hospital Canselor Tuanku Muhriz UKM (HCTM-UKM),
Head of the Gyne-Oncology and Minimally Invasive Surgery Units,
Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM),
Kuala Lumpur, Malaysia

Evaluation of cancer risks in IIM: A Hong Kong perspective on IMACS stratification

Idiopathic inflammatory myopathies (IIM) is a group of autoimmune disorders characterized by chronic muscle inflammation, presenting with varying clinical features, treatment responses, and prognoses.¹ Recently, the International Myositis Assessment and Clinical Studies Group (IMACS) released a set

30 Oct 2024

Dr. So, Ho

Assistant Professor,
Division of Rheumatology,
Department of Medicine and Therapeutics,
Faculty of Medicine,
The Chinese University of Hong Kong

Dr. Tang, Yan-Ki Iris

Clinical Assistant Professor of Practice,
Department of Medicine,
Li Ka Shing Faculty of Medicine,
The University of Hong Kong

ESMO 2025

October 17-21 , 2025 | Berlin, Germany

Optimizing diagnosis and surveillance of von Hippel-Lindau disease: HKSUO-HKNOS joint expert consensus

ONCOLOGY UROLOGY

27 Jul 2026

HKSUO Annual Scientific Meeting 2026

Cheung KM. HKSUO-HKNOS consensus in diagnosis and surveillance for von Hippel-Lindau (VHL) disease in a multidisciplinary care approach. Presented at the HKSUO Annual Scientific Meeting 2026; January 17-18, 2026.

Dual immunotherapy combination in pre-treated HCC: A case study in achieving 10-year remission

In an interview with Professor Yau, Chung-Cheung Thomas, he shared a case of 10-year survival in a patient with metastatic aHCC in the second-line setting managed with dual immune checkpoint inhibitors nivolumab + ipilimumab. Dr. Wong, Sum-Lung Jeffrey also provided insights into data from the CheckMate 040 trial and its Asian subgroup analysis, highlighting not only the efficacy and durability of the dual immune checkpoint inhibitors but also their manageable safety profile. The combination of nivolumab + ipilimumab marks a paradigm shift in HCC treatment, offering hope for long-term survival in a disease once considered universally fatal.

26 Jan 2026

Professor Yau, Chung-Cheung Thomas

Clinical Associate Professor,
Centre of Cancer Medicine/
Department of Medicine
School of Clinical Medicine,
LKS Faculty of Medicine,
The University of Hong Kong

Dr. Wong, Sum-Lung Jeffrey

Fellow in Medical Oncology

CAPItello-281: FDA approves capivasertib + abiraterone for PTEN-deficient advanced prostate cancer

The CAPItello-281 phase 3 trial evaluated capivasertib + abiraterone in patients with phosphatase and tensin homolog (PTEN)-deficient metastatic prostate cancer. The dual-pathway inhibition strategy significantly improved median radiographic PFS compared to placebo. This FDA approved targeted regimen offers an effective therapeutic strategy for this aggressive disease.

28 Aug 2026

Low on-treatment PSA predicts improved long-term survival in advanced prostate cancer

A STAMPEDE trial analysis confirmed that achieving an on-treatment prostate-specific antigen (PSA) ≤0.2ng/mL as early as 6 weeks predicts favorable long-term survival in advanced prostate cancer. However, baseline metastatic volume and nodal status remain heavily prognostic, indicating that combining imaging and PSA response optimizes survival predictions.

22 Jun 2026

OBSTETRICS & GYNECOLOGY ONCOLOGY DIABETES & ENDOCRINOLOGY CARDIOLOGY

Double jeopardy: Obesity + CVD linked to higher postmenopausal breast cancer risk

17 Sep 2025